These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31231391)

  • 1. Clinical and Immunological Profile of Anti-factor H Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database.
    Puraswani M; Khandelwal P; Saini H; Saini S; Gurjar BS; Sinha A; Shende RP; Maiti TK; Singh AK; Kanga U; Ali U; Agarwal I; Anand K; Prasad N; Rajendran P; Sinha R; Vasudevan A; Saxena A; Agarwal S; Hari P; Sahu A; Rath S; Bagga A
    Front Immunol; 2019; 10():1282. PubMed ID: 31231391
    [No Abstract]   [Full Text] [Related]  

  • 2. Abbreviated protocol of plasma exchanges for patients with anti-factor H associated hemolytic uremic syndrome.
    Thangaraju S; Khandelwal P; Mishra K; Kumar M; Puraswani M; Saini R; Hari P; Coshic P; Sinha A; Bagga A
    Pediatr Nephrol; 2024 Jul; 39(7):2091-2097. PubMed ID: 38270601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CFH-associated hemolytic uremic syndrome: do we still need plasma exchange?
    Ferri M; Zotta F; Donadelli R; Dossier C; Duneton C; El-Sissy C; Fremeau-Bacchi V; Kwon T; Quadri L; Pasini A; Sellier-Leclerc AL; Vivarelli M; Hogan J
    Pediatr Nephrol; 2024 Nov; 39(11):3263-3269. PubMed ID: 38632123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome.
    Nozal P; Bernabéu-Herrero ME; Uzonyi B; Szilágyi Á; Hyvärinen S; Prohászka Z; Jokiranta TS; Sánchez-Corral P; López-Trascasa M; Józsi M
    Mol Immunol; 2016 Feb; 70():47-55. PubMed ID: 26703217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-complement-factor H-associated glomerulopathies.
    Durey MA; Sinha A; Togarsimalemath SK; Bagga A
    Nat Rev Nephrol; 2016 Sep; 12(9):563-78. PubMed ID: 27452363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor H autoantibody is associated with atypical hemolytic uremic syndrome in children in the United Kingdom and Ireland.
    Brocklebank V; Johnson S; Sheerin TP; Marks SD; Gilbert RD; Tyerman K; Kinoshita M; Awan A; Kaur A; Webb N; Hegde S; Finlay E; Fitzpatrick M; Walsh PR; Wong EKS; Booth C; Kerecuk L; Salama AD; Almond M; Inward C; Goodship TH; Sheerin NS; Marchbank KJ; Kavanagh D
    Kidney Int; 2017 Nov; 92(5):1261-1271. PubMed ID: 28750931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
    Blanc C; Togarsimalemath SK; Chauvet S; Le Quintrec M; Moulin B; Buchler M; Jokiranta TS; Roumenina LT; Fremeaux-Bacchi V; Dragon-Durey MA
    J Immunol; 2015 Jun; 194(11):5129-38. PubMed ID: 25917093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-factor H antibody associated hemolytic uremic syndrome following SARS-CoV-2 infection.
    Khandelwal P; Krishnasamy S; Govindarajan S; Kumar M; Marik B; Sinha A; Hari P; Bagga A
    Pediatr Nephrol; 2022 Sep; 37(9):2151-2156. PubMed ID: 35089377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety.
    Khandelwal P; Thomas CC; Rathi BS; Hari P; Tiwari AN; Sinha A; Bagga A
    J Clin Apher; 2019 Oct; 34(5):555-562. PubMed ID: 31173399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of plasma exchange and immunosuppressive medications on antibody titers and outcome in anti-complement factor H antibody-associated hemolytic uremic syndrome.
    Khandelwal P; Gupta A; Sinha A; Saini S; Hari P; Dragon Durey MA; Bagga A
    Pediatr Nephrol; 2015 Mar; 30(3):451-7. PubMed ID: 25217328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.
    Valoti E; Alberti M; Iatropoulos P; Piras R; Mele C; Breno M; Cremaschi A; Bresin E; Donadelli R; Alizzi S; Amoroso A; Benigni A; Remuzzi G; Noris M
    Front Immunol; 2019; 10():853. PubMed ID: 31118930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overactivation of Complement Alternative Pathway in Postpartum Atypical Hemolytic Uremic Syndrome Patients with Renal Involvement.
    Song D; Yu XJ; Wang FM; Xu BN; He YD; Chen Q; Wang SX; Yu F; Song WC; Zhao MH
    Am J Reprod Immunol; 2015 Oct; 74(4):345-56. PubMed ID: 26011580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical and laboratory features of Chinese Han anti-factor H autoantibody-associated hemolytic uremic syndrome.
    Song D; Liu XR; Chen Z; Xiao HJ; Ding J; Sun SZ; Liu HY; Guo WY; Wang SX; Yu F; Zhao MH;
    Pediatr Nephrol; 2017 May; 32(5):811-822. PubMed ID: 28035470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation.
    Ueda Y; Miwa T; Ito D; Kim H; Sato S; Gullipalli D; Zhou L; Golla M; Song D; Dunaief JL; Palmer MB; Song WC
    Kidney Int; 2019 Jul; 96(1):67-79. PubMed ID: 30910380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-factor B antibodies in atypical hemolytic uremic syndrome.
    Khandelwal P; Nambiar S; Saini R; Saini S; Coshic P; Sinha A; Hari P; Palanichamy JK; Bagga A
    Pediatr Nephrol; 2024 Jun; 39(6):1909-1916. PubMed ID: 38252289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies.
    Boyer O; Balzamo E; Charbit M; Biebuyck-Gougé N; Salomon R; Dragon-Durey MA; Frémeaux-Bacchi V; Niaudet P
    Am J Kidney Dis; 2010 May; 55(5):923-7. PubMed ID: 20202729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distal Angiopathy and Atypical Hemolytic Uremic Syndrome: Clinical and Functional Properties of an Anti-Factor H IgAλ Antibody.
    Rigothier C; Delmas Y; Roumenina LT; Contin-Bordes C; Lepreux S; Bridoux F; Goujon JM; Bachelet T; Touchard G; Frémeaux-Bacchi V; Combe C
    Am J Kidney Dis; 2015 Aug; 66(2):331-6. PubMed ID: 26015278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor H Autoantibodies and Complement-Mediated Diseases.
    Zhang Y; Ghiringhelli Borsa N; Shao D; Dopler A; Jones MB; Meyer NC; Pitcher GR; Taylor AO; Nester CM; Schmidt CQ; Smith RJH
    Front Immunol; 2020; 11():607211. PubMed ID: 33384694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses.
    Sana G; Dragon-Durey MA; Charbit M; Bouchireb K; Rousset-Rouvière C; Bérard E; Salomon R; Frémeaux-Bacchi V; Niaudet P; Boyer O
    Pediatr Nephrol; 2014 Jan; 29(1):75-83. PubMed ID: 23868108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome.
    Cugno M; Berra S; Depetri F; Tedeschi S; Griffini S; Grovetti E; Caccia S; Cresseri D; Messa P; Testa S; Giglio F; Peyvandi F; Ardissino G
    J Am Soc Nephrol; 2021 May; 32(5):1227-1235. PubMed ID: 33712527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.